news

CEA Industries Files Registration Statement for its $500M PIPE. CEO David Namdar Releases Letter to Shareholders

New York, Sept. 21, 2025 (GLOBE NEWSWIRE) -- CEA Industries Inc. (Nasdaq: BNC), (“BNC” or the “Company”), the world’s leading…

9 months ago

ICEX and SOSA Launch Desafa San Francisco to Accelerate Spanish Startups in Silicon Valley

Credit: Maarten van den Heuvel // San Francisco, United States. MADRID, Sept. 21, 2025 (GLOBE NEWSWIRE) -- Following the success…

9 months ago

Tracer Launches Initial Exchange Offering on Coinstore: Building a Trusted RWA Ecosystem for Carbon Removal

Singapore, Sept. 20, 2025 (GLOBE NEWSWIRE) -- 15 September 2025 Singapore, Singapore — Coinstore has announced the official IEO of…

9 months ago

VT Markets launches brand film to showcase shared values with NUFC to mark the beginning of the partnership’s second year

SYDNEY, Sept. 22, 2025 /PRNewswire/ -- VT Markets, a leading multi-asset broker, is celebrating the success of its ongoing partnership with…

9 months ago

SEMI Issues Statement on U.S. H1-B Visa Policy Announcement

MILPITAS, Calif., Sept. 22, 2025 /PRNewswire/ -- SEMI, the industry association serving the global electronics design and manufacturing supply chain,…

9 months ago

Osstem Implant Expands World-Class Clinical Education in India, Accelerating CSR Efforts

OIC India Enhances On-Site Capabilities with Structured Clinical and Digital Dentistry Training SEOUL, South Korea, Sept. 22, 2025 /PRNewswire/ --…

9 months ago

Bybit Becomes the First Exchange to List ASTER, Launches Exclusive Campaigns With Rewards up to 100,000 USDT

DUBAI, UAE, Sept. 22, 2025 /PRNewswire/ -- Bybit, the world's second-largest cryptocurrency exchange by trading volume, today announced it has…

9 months ago

Patients Taking AUSTEDO XR (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction

Of the 209 patients with tardive dyskinesia (TD) that were surveyed, >94% reported movement improvement once treated with AUSTEDO XR®…

9 months ago

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-‘749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events observed with…

9 months ago

PharmAla Files Amended and Restated Preliminary Base Shelf Prospectus

TORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology…

9 months ago